Chest Medicine (all articles)
COVID-19 is 10 times deadlier for people with Down syndrome, raising calls for early vaccination
17 Dec, 2020 | 08:51h | UTC
Study: Filtration efficiency of face masks used by the public during the COVID-19 pandemic are, in many cases, nearly equivalent to or better than their non-N95 respirator medical mask counterparts
17 Dec, 2020 | 08:43h | UTCEditorial: Filtration Efficiency of Face Masks Used by the Public During the COVID-19 Pandemic
Commentary on Twitter
Marked reassurance on the value of cloth masks.
A new @JAMAInternalMed assessment today https://t.co/bTrurKeG71 Attention to fit is key, such as aluminum nose bridge, ties, no beard, etc ?? @Phillip_Clapp @UNC_SOM pic.twitter.com/ZCMTT2OWXc— Eric Topol (@EricTopol) December 11, 2020
Individual and community-level risk predictor for COVID-19 mortality in the US, with risk calculator
16 Dec, 2020 | 09:42h | UTCIndividual and community-level risk for COVID-19 mortality in the United States – Nature Medicine
Calculator: Covid-19 risk
Commentary on Twitter
New @NatureMedicine
What is your individualized risk of dying from covid19?https://t.co/Bg61t3raVNhttps://t.co/tQGH0ilsmR (1.1X for me) pic.twitter.com/9pkwyCUAVw— Eric Topol (@EricTopol) December 11, 2020
COVID-19 mimics on chest CT: a pictorial review and radiologic guide
17 Dec, 2020 | 08:37h | UTC
Video (5min): Ivermectin for COVID-19 | A Doctor Explains
16 Dec, 2020 | 09:43h | UTCIvermectin For COVID-19 | A Doctor Explains – ZDoggMD
ACR Guidance for pediatric patients with multisystem inflammatory syndrome in children associated with SARS‐CoV‐2
16 Dec, 2020 | 09:32h | UTC
Report: Lung transplantation for 3 patients with severe COVID-19
16 Dec, 2020 | 09:34h | UTCLung transplantation for patients with severe COVID-19 – Science Translational Medicine
Commentaries: COVID-19 can damage lungs so badly that ‘only hope’ is transplant – MedicalXpress
Commentary on Twitter
Case reports from 3 patients with severe #COVID19 who received lung transplants show the disease can cause extensive lung damage similar to that seen in pulmonary #fibrosis, and hints transplantation may be a viable treatment. @NUFeinbergMed @ScienceTM https://t.co/wXi0tx8gFg pic.twitter.com/vyerJLlJxi
— Science Magazine (@ScienceMagazine) November 30, 2020
Consensus Guideline: Defining and managing COVID-19-associated pulmonary aspergillosis
15 Dec, 2020 | 01:42h | UTC
The coronavirus at 1: A year into the pandemic, what scientists know about how it spreads, infects, and sickens
15 Dec, 2020 | 01:42h | UTC
[Preprint] RECOVERY trial: Azithromycin does not improve outcomes in hospitalized patients with COVID-19
15 Dec, 2020 | 01:44h | UTCNews release: RECOVERY trial finds no benefit from azithromycin in patients hospitalised with COVID-19
Commentary on Twitter
New RECOVERY result. In patients hospitalised with COVID-19, azithromycin did not provide any clinical benefit. 28 day mortality (19% vs 19%) (rate ratio 1·00; 95% confidence interval [CI] 0·90-1·12; p=0·99). No effect on secondary outcomes either.https://t.co/PTklz40WKr pic.twitter.com/NCzvRIND0S
— Peter Horby (@PeterHorby) December 14, 2020
Critical review: “I’m upset about the RELAX trial” (study showing a lower PEEP strategy is noninferior to a higher PEEP strategy in ICU patients without ARDS)
15 Dec, 2020 | 01:27h | UTCI’m upset about the RELAX trial – PulmCrit
Original study and commentaries: Randomized trial: Among patients in the ICU receiving invasive ventilation, a strategy with lower PEEP was noninferior to a strategy using higher PEEP
Commentary from the author on Twitter
RELAX trial
?♂️PEEP 8 cm vs. lowest possible PEEP (as low as zero!) among patients without ARDS
?♂️no difference in primary endpoints
?♂️low-PEEP caused lower PO2/FiO2 ratios, higher driving pressures, more need for rescue therapy ?https://t.co/fGFiQyn3jY pic.twitter.com/yi2hN3yBZi— ???? ?????? ? (@PulmCrit) December 14, 2020
Randomized trial: Baricitinib plus remdesivir reduce recovery time in patients with COVID-19
13 Dec, 2020 | 23:31h | UTCBaricitinib plus Remdesivir for Hospitalized Adults with Covid-19 – New England Journal of Medicine
Commentary: Baricitinib plus remdesivir shows promise for treating COVID-19 – NIH News Releases
Commentary on Twitter
Not sure how to interpret a trial for a drug plus Remdesivir vs Remdesivir alone when you don't know if Remdesivir works. @NEJM today for this combo, which has already received FDA EUAhttps://t.co/tpmHPFPJX1 pic.twitter.com/Tmue99oJnV
— Eric Topol (@EricTopol) December 11, 2020
Meta-analysis: Efficacy and harms of remdesivir for the treatment of COVID-19. “Until stronger evidence emerges, we cannot conclude that remdesivir is efficacious for treating COVID-19”.
13 Dec, 2020 | 23:27h | UTC
Video: Coronavirus vaccine update with Anthony Fauci
13 Dec, 2020 | 23:25h | UTCCoronavirus Vaccine Update With Anthony Fauci – JAMA
A systematic review of corticosteroid treatment for noncritically ill patients with COVID-19 – corticosteroid treatment is not recommended for patients with mild or moderate COVID-19
13 Dec, 2020 | 23:26h | UTC
Just published: Pfizer vaccine confers 95% protection against Covid-19
11 Dec, 2020 | 09:32h | UTCSafety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine – New England Journal of Medicine
Editorial: SARS-CoV-2 Vaccination — An Ounce (Actually, Much Less) of Prevention
Commentary: Pfizer vaccine results published in peer-reviewed journal – MedicalXpress
Related: FDA advisory panel endorses Pfizer/BioNTech Covid-19 vaccine – STAT
Commentary on Twitter (Thread – Click for more)
I read the @pfizer @US_FDA vaccine briefing doc
3 take homes (1 obvious, 2 new takes I haven't seen before)
1. Efficacy is great to prevent #COVID19 & promising for severe illness (this has been said many times before)
Moving on…https://t.co/WLrEpjmuO8
— Anil Makam (@AnilMakam) December 10, 2020
Randomized trial: Trimethoprim-Sulfamethoxazole does not benefit patients with moderate and severe idiopathic pulmonary fibrosis
13 Dec, 2020 | 23:14h | UTCCommentary: Idiopathic pulmonary fibrosis: Co-trimoxazole therapy did not prevent disease progression – MedicalResearch
Commentary on Twitter
In this RCT oral co-trimoxazole (TMP-SMX) did not reduce a composite outcome of time to death, transplant, or hospitalization vs placebo in patients w moderate- severe idiopathic pulmonary fibrosis (#IPF) https://t.co/fsNxwynG1s @MarkSpe90122390
— JAMA (@JAMA_current) December 9, 2020
Healthcare workers 7 times as likely to have severe COVID-19 as other workers
11 Dec, 2020 | 09:29h | UTCCommentary: Healthcare workers 7 times as likely to have severe COVID-19 as other workers – BMJ
Commentary on Twitter
Of essential workers, who has the highest risk of severe #COVID19?
Healthcare workforce >7X.
Non-white >8X.https://t.co/ZBUJYccXlT (compared with non-essential workers)
A @uk_biobank study from >120,000 participants
[NB: current issue with link] pic.twitter.com/UZmIO69G4O— Eric Topol (@EricTopol) December 9, 2020
Long Covid: Study shows persistence of symptoms in a third of ambulatory patients 30 to 45 days after diagnosis
11 Dec, 2020 | 09:27h | UTCCommentary: COVID-19: persistent symptoms in one third of cases – Université de Genève
Commentary on Twitter
Study of 669 people who had #COVID19 during the first wave in Switzerland. Of 510 who were followed up for 30-45 days, 32% still had at least one symptom.
Fatigue, shortness of breath, and loss of smell or taste were the most common symptoms. #LongCovidhttps://t.co/pDB6nuZWTn pic.twitter.com/bbt9c3LFXl
— Dr Zoë Hyde (@DrZoeHyde) December 8, 2020
Randomized trial: Among patients in the ICU receiving invasive ventilation, a strategy with lower PEEP was noninferior to a strategy using higher PEEP
11 Dec, 2020 | 09:22h | UTCEditorial: Searching for the Optimal PEEP in Patients Without ARDS: High, Low, or in Between?
Video: Effect of Lower vs Higher PEEP Strategy on Ventilator-Free Days in ICU Patients Without ARDS
Commentary on Twitter
Effect of a Lower vs Higher PEEP Strategy on Ventilator-Free Days in ICU Patients Without ARDS https://t.co/h6IozSLUeS via @JAMA_current part of @JAMANetwork There is no size that fits all. PEEP titration – way to go.
— Matthias Eikermann (@MatthiasEikerm1) December 10, 2020
Systematic review: Men with COVID-19 have almost three times the risk of requiring ICU admission and a higher risk of death
10 Dec, 2020 | 08:45h | UTCCommentary: Men face ‘almost three times the odds’ of ICU admission for Covid-19, study says – CNN AND Men with COVID-19 three times more likely to need intensive care: study – MedicalXpress
Commentary on Twitter
Men w/ COVID19 are 3 times more likely to need intensive care & are at significantly higher risk of dying from the virus than women. New research analyzed over 3 million confirmed cases from 46 countries and 44 states. 2 links: https://t.co/g9nYKWxzcv
andhttps://t.co/ZOIfSYImWi— delthia ricks ? (@DelthiaRicks) December 9, 2020
UK to refine allergy warning on Pfizer vaccine sparked by two adverse reactions
10 Dec, 2020 | 08:41h | UTCUK to refine allergy warning on Pfizer vaccine sparked by two adverse reactions – Reuters
See also: UK probes whether COVID-19 vaccine caused allergic reactions – Associated Press AND NHS told not to give Covid vaccine to those with history of allergic reactions – The Guardian
CDC releases new ventilation guidelines for indoor environments to reduce Covid-19 risk
9 Dec, 2020 | 08:23h | UTCCDC Releases New Ventilation Guidelines For Indoor Environments To Reduce Covid-19 Risk – Forbes
CDC Guideline: Ventilation
Related podcast: Air Handling Standards for Increasing the Safety of Indoor Spaces During the COVID-19 Pandemic – JAMA
Just published: AstraZeneca-Oxford Covid-19 vaccine shows moderate efficacy, but questions remain about the most effective dosing regimen
9 Dec, 2020 | 08:25h | UTCCommentaries: Oxford COVID vaccine paper highlights lingering unknowns about results – Nature AND Detailed data on AstraZeneca-Oxford Covid-19 vaccine show it has moderate efficacy – STAT AND Oxford–AstraZeneca COVID-19 vaccine efficacy – The Lancet AND Oxford COVID-19 vaccine is safe and protects against disease, first published results from phase 3 trials – The Lancet AND Expert reaction to a study on the results of phase 3 human trials of the Oxford/AZ COVID-19 vaccine – Science Media Centre
“COVID-19: when are you most infectious?” This commentary from the authors of a recent meta-analysis highlights the findings that infectiousness peaks within the first 5 days of symptom onset
10 Dec, 2020 | 08:38h | UTCCOVID-19: when are you most infectious? – The Conversation
Original study and commentaries: Meta-analysis: SARSCoV2 most contagious within the first 5 days of symptom onset